A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)

The main aim of this study is to learn about the time between the start and stop of treatment with brigatinib in Chinese participants with non-small-cell lung cancer (NSCLC) and who have been positively diagnosed with having the anaplastic lymphoma kinase (ALK) gene. Other study aims are to learn about the progression of NSCLC and participants' response to treatment with brigatinib.

Inclusion CriteriaAge ≥ 18 years.Participant with histologically/cytologically confirmed locally advanced or metastatic NSCLC.Participants with ALK gene rearrangement confirmed by local hospital medical records.During the period from September 1, 2022 to December 31, 2023, participants who received brigatinib as first line treatment confirmed by medical records.Participants who have at least one medical record after the start of brigatinib treatment.Exclusion CriteriaParticipants participated in NSCLC-related interventional clinical trials after locally advanced or metastatic NSCLC diagnosis and during brigatinib treatment.Previously received any other TKIs, including ALK-targeted TKIs.Previously received more than 1 regimen of systemic anticancer therapy for locally advanced or metastatic disease.Participants have been diagnosed as malignancies (excluding completely resected basal cell carcinoma, bladder carcinoma in situ, cervical carcinoma in situ) in addition to NSCLC within the past 5 years.